Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, crossover study

Diabetes, Obesity and Metabolism

Volumn 17, Issue 8, 2015, Pages 800-804

  Nishimura, R ^a   Osonoi, T ^b   Kanada, S ^c   Jinnouchi, H ^d   Sugio, K ^e   Omiya, H ^e   Ubukata, M ^e   Sakai, S ^e   Samukawa, Y ^e  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Naka Kinen Clinic   (Japan)

^c OCROM Clinic   (Japan)

^d Jinnouchi Hospital   (Japan)

^e TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

24 h glucose variability; Continuous glucose monitoring; Luseogliflozin; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; LUSEOGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SORBITOL;

BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; JAPANESE (CITIZEN); LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; JAPAN; MEAL; POSTPRANDIAL STATE; PROCEDURES;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; MEALS; POSTPRANDIAL PERIOD; SORBITOL;

EID: 84937815761     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12481     Document Type: Letter

References (10)

1. Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs 2014; 74: 945-950.
2. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245-1255.
3. Nishimura R, Tanaka Y, Koiwai K et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 2015; 14: 11.
4. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
5. Jurczak MJ, Lee HY, Birkenfeld AL et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60: 890-898.
6. Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin 2014; 30: 1219-1230.
7. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin 2014; 30: 1231-1244.
8. Sasaki T, Seino Y, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. TS-071, a novel potent and highly selective renal sodium-glucose co-transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. Diabetologia 2011; 54: S345-S346.
9. Yamamoto K, Uchida S, Kitano K et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011; 164: 181-191.
10. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393.